- Home
- REX vs PLRX Comparison
REX vs PLRX Comparison
Compare REX & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REX | PLRX |
|---|---|---|
| Founded | 1980 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 79.9M |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | REX | PLRX |
|---|---|---|
| Price | $41.30 | $1.36 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 4 |
| Target Price | ★ $25.00 | $2.67 |
| AVG Volume (30 Days) | 139.2K | ★ 620.9K |
| Earning Date | 01-01-0001 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.97 |
| EPS | ★ 1.18 | N/A |
| Revenue | ★ $642,491,000.00 | N/A |
| Revenue This Year | $3.27 | N/A |
| Revenue Next Year | $17.11 | N/A |
| P/E Ratio | $34.93 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $30.02 | $1.09 |
| 52 Week High | $64.95 | $1.95 |
Technical Indicators
Market Signals| Indicator | REX | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 79.44 | 56.70 |
| Support Level | $31.06 | $1.12 |
| Resistance Level | $55.35 | $1.36 |
| Average True Range (ATR) | 1.31 | 0.06 |
| MACD | 0.42 | 0.00 |
| Stochastic Oscillator | 93.23 | 56.10 |
Price Performance
Historical ComparisonAbout REX REX American Resources Corporation
REX American Resources Corp operates as a holding company, which engages in investment in alternative energy and ethanol production entities. Its operating segments include Ethanol and By-Products. Its products include dried distillers grains, modified distillers grains, and non-food grade corn oil.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.